IPSC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Century Therapeutics Inc (IPSC) is not a strong buy for a beginner, long-term investor at this time. While the technical indicators show some bullish momentum, the lack of significant positive catalysts, weak financial performance, and hedge fund selling trends suggest caution. The stock may be worth monitoring for future developments, but it does not currently align with the investor's goals and risk tolerance.
The stock shows bullish momentum with MACD positively expanding and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). RSI is in the neutral zone at 72.255, and the price is near the R1 resistance level of 2.275. However, the stock's candlestick analysis suggests a 30% chance of a slight decline in the short term (-1.19% in the next day, -1.98% in the next week).
The company's lead asset, CNTY-813, has shown intriguing preclinical data for type 1 diabetes, which could create long-term shareholder value as the pipeline advances. Analysts have initiated coverage with a Buy rating.
Hedge funds are selling heavily, with a 179.43% increase in selling over the last quarter. Financial performance is weak, with revenue dropping to 0 in Q3 2025 and net income still negative. No significant news or recent congress trading data is available to support a positive sentiment.
In Q3 2025, revenue dropped to 0 (-100% YoY), while net income improved slightly to -$34.42M (+10.24% YoY). EPS also increased to -0.4 (+8.11% YoY), but the company remains unprofitable. Gross margin remains at 100%.
TD Cowen initiated coverage with a Buy rating, citing potential long-term value from the company's pipeline, particularly its lead asset CNTY-813. However, no price target was provided.
